U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma 14/02/2020 Medications SANTA MONICA, Calif.–(BUSINESS WIRE)–Feb. 10, 2020– Kite, a Gilead Company (Nasdaq: GILD), Read more